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INTRODUCTION
It is a real challenge for an oral health professional 
to provide satisfactory dental care to patients. Most 
oral health conditions can be prevented or treated 
successfully with education and regular dental and 
dental hygiene care. Unfortunately, the one oral 
disease that can be life-threatening is the disease 
that is often overlooked with respect to emphasis on 
prevention and early detection in clinical practice 
settings. 
 
Research states that Oral cancer is the 6th most 
common malignancy in the world.1 It is estimated 
that over 640,000 new cases will be identified 
worldwide on a yearly basis. 
 
The prognosis for oral and pharyngeal cancer varies 
depending upon when it is identified. Approximately 
83 percent of patients with localized lesions survive 
beyond five years.2 Prognosis is significantly worse 
when oral cancer has metastasized resulting in a 28 
percent survival rate.3 Oral cancer has a high risk of 
producing second primary tumors. If a patient 
survives the initial diagnosis and treatment, they 
still have up to a 20 time higher risk of developing a 
second cancer.4 
 
These statistics can be improved with emphasis on 
prevention and early detection. Unfortunately, oral 
and pharyngeal cancer is routinely discovered at a 
later stage in development when the cancer has 
already metastasized. Part of the problem is that 
early cancer is painless and not easily recognized by 
the patient. The other contributing element is that 
dental practitioners are not placing the same level of 
importance on early detection of oral cancer as they 
place on the prevention and treatment of caries and 
periodontal disease.6 Therefore, this paper highlight 
key elements of oral cancer as well as current 
approaches used for early detection. 
 
RISK FACTORS/ETIOLOGY OF ORAL 
CANCER 
• History of tobacco use (all forms) 
• Alcohol consumption 
• Sexual history (multiple sex partners, 
unprotected sex, exposure to HPV) 
• Exposure to ultraviolet light 
• Exposure to ionizing radiation, arsenic or 
industrial chemicals 
• Chronic irritation (poor oral hygiene, poor 
restorative dentistry) 
• Pre-existing scars and burns 
• Family history of cancer 
• Personal history of cancer 
• Age > 40 years 
• Mucosal diseases (iron deficiency associated 
with Plummer-Vinson Syndrome, lichen planus) 
• Immune system suppression 
• Gender 
• Race 
 
WARNING SIGNS OF ORAL CANCER 
 A lump or thickening in the oral soft tissues 
 Soreness or difficulty in chewing or swallowing 
 Ear pain 
 Difficulty moving the jaw or tongue 
 Hoarseness 
 Numbness of the tongue or other areas of the 
mouth 
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Oral cancer is a common disease which affects individuals of mainly the older age group. If diagnosed at later stages, the prognosis is poor. 
In this review, the various techniques for diagnosis of oral cancer such as screening of the patient by conventional oral examination, 
supravital staining, visual adjunctive aids, biopsy etc. have been discussed. The traditional treatments include surgery, chemotherapy and 
radiotherapy. Newer modalities include gene therapy, immunotherapy, etc. have proven to be successful to some extent. Thorough 
knowledge of the disease and timely diagnosis by the dental professional can prevent metastasis. 
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 Swelling of the jaw that causes dentures to fit  
poorly or become uncomfortable 
 Repeated bleeding from the mouth or throat 
 Red, white, or discolored lesions in the mouth or 
on the lips 
 
SIGNS AND SYMPTOMS OF ORAL CANCER 
• Intraoral swelling on lips or neck 
• Crust on lip 
• Bleeding 
• Rough spot 
• Change in bite or occlusion 
• Pain or tenderness 
• Denture no longer fits 
• Loose tooth or teeth 
• Restriction of tongue or jaw movements 
• Taste change 
• Paraesthesia 
• Chronic cough 
• Dry mouth 
• Speech changes 
• Color change 
• Symptoms related to primary tumor elsewhere 
 
  
Researchers advocate the use of comprehensive oral 
examination (COE) as the "gold standard" for early 
detection.6  
 
SCREENING TOOLS FOR ORAL CANCER 
• Visual inspection 
• Self- Examination 
• Toluidine blue 
• Fluorescence imaging 
• Exfoliate cytology/Brush biopsy 
• Saliva Examination 
 
 
SCREENING PROTOCOL  
Early detection of oral cancer and related 
premalignancy requires an appropriate screening 
and diagnosis protocol. It has been recommended 
that all adult patients 18 and over be screened 
annually,7 even if medical and dental histories elicit 
no risk factors. Known-risk patients should be 
screened every six months.  
 
The screening protocol should include medical and 
dental history, unaided and aided visual 
examination, and palpation. All oral structures must 
be thoroughly examined, and any abnormalities 
should be recorded on a mouth map. If suspicious 
lesions are found during the screening procedure, 
the lesion must be biopsied or the patient referred to 
a specialist for further evaluation.  
 
BIOPSY PROTOCOL  
The two basic biopsy techniques for definitive 
diagnosis of oral mucosal lesions are incisional 
biopsy and excisional biopsy. The brush biopsy 
(CDx) is a third type of biopsy that can be used as a 
preliminary diagnostic tool. The brush biopsyuses a 
stiff brush to obtain a full-thickness sampling of 
epithelial cells for examination, in patients with 
mucosal lesions.  
 
The brush biopsy may also be useful as an 
intermittent preliminary diagnostic technique in 
patients under observation.8 While brush biopsies 
are practical, simple to perform, and less invasive 
than an incisional or excisional biopsy, they are 
insufficient to provide a definitive diagnosis. 
Incisional or excisional biopsy is the standard-of-
care for definitive diagnosis.  
 
CURRENT TOPICS IN CANCER SCREENING 
 
TOLUIDINE BLUE: Toluidine blue is a vital stain 
that binds to nuclear material and preferentially 
stains tissues with high rates of cellular proliferation.  
 
Toluidine blue can be associated with a high false 
positive and high false negative rate. For example, 
50% of oral lichen planus lesions were positive and 
only 42% of dysplasias stained positively.9 Therefore, 
the provider must be careful not to overextend the 
utility of this tool. Toluidine blue has also been 
proposed as a tool to predict progression of oral 
dysplasia to cancer. In one study, toluidine blue 
stained lesions with high-risk histologic features, 
with staining correlated to patient outcome.10 There 
is no evidence to support the use of toluidine blue as 
an oral cancer screening tool for the general 
population 
 
TISSUE FLUORESCENCE: Certain cellular 
molecules, especially those within mitochondria and 
lysosomes, absorb the energy from light of specific 
wavelength. When these molecules move back to 
their unexcited state, the absorbed energy is 
released. This energy is referred to as fluorescence 
emissions. Porphyrins in erythrocytes also 
contribute to autofluorescence. Oral cancer cells 
have different autofluorescence emission relative to 
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normal oral mucosa. Technology, such as VELscope,  
has been developed to capitalize on this difference 
in autofluorescence between cancer and normal 
tissue and to use this approach to detect pathologic 
lesions in the oral cavity. 
 
TISSUE REFLECTANCE: Chemiluminescence, or 
tissue reflectance, is an adjunctive screening tool 
that is used to detect cervical premalignant or 
malignant lesions. Two systems using 
chemiluminescence developed for the oral cavity are 
ViziLite® Plus and MicroLux DL. The increased 
nuclear to cytoplasmic ratio characteristic of 
squamous cell carcinoma increases light reflectance 
relative to normal epithelium. The sensitivity of the 
chemiluminescence devices for highlighting 
potentially pathologic lesions is high; however, 
benign lesions, such as leukoedema and traumatic 
ulcers, test positive examination under standard 
incandescent lighting. Oh and Laskin reported that 
the use of ViziLite® actually made visualizing lesions 
more difficult due to the distracting highlights it 
created. At best, tissue reflectance technology can be 
used as an adjunctive screening tool to the 
conventional oral examination. A scalpel biopsy of 
suspicious lesions is required. 
 
BRUSH CYTOLOGY: The brush biopsy (Oral CDx® 
from CDx Laboratories) is intended for oral lesions 
that appear innocuous and would not normally be 
biopsied by the provider. The brush biopsy is 
intended to be an adjunct diagnostic tool and not a 
screening tool. Demonstrating efficacy for the 
diagnosis of suspicious oral lesions with brush 
cytology is not easy. The population investigated 
must have lesions that are not already highly 
suspicious for malignancy, and all lesions in the 
population must be subjected to surgical biopsy. 
 
GENOMICS: The human genome project, 
completed in 2002, was to revolutionize surgery and 
medicine. Scientists predicted that once the entire 
human genome sequence was known that many 
cancers, including oral cancer, would be curable.  
 
However, our comprehensive understanding of the 
human genome has not cured cancer 
 
CONCLUSION 
The ability to identify lesions and to predict which 
lesions will undergo malignant transformation 
would facilitate early diagnosis and subsequent 
disease management tailored to the individual 
patient. The ultimate goals are to reduce both 
mortality and morbidity, and to improve patients’ 
quality of life. 
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